Satya Das Archives
Clinical score can guide PRRT therapy decisions for neuroendocrine tumors
Jan. 19, 2022—A clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide peptide receptor radionuclide therapy treatment decisions.
Shifts in neuroendocrine cancer clinical trial design
Nov. 2, 2021—Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.
Clinical trial tests ATR inhibitor in difficult-to-treat cancers
Sep. 23, 2021— by Tom Wilemon A clinical trial has been launched to test a new targeted therapy in patients with advanced and difficult-to-treat cancers. Satya Das, MD, MSCI, assistant professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), is the national principal investigator for the trial (NCT04514497) that is now enrolling people with metastatic small cell lung...
Das lands support for neuroendocrine tumor research
Mar. 5, 2020—Satya Das, MD, has been awarded a $300,000 grant for a two-year period by the Neuroendocrine Tumor Research Foundation.
